Sumitomo Mitsui Trust Group
MRNA icon

Sumitomo Mitsui Trust Group’s Moderna MRNA Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
20,757
+214
+1% +$11.1K ﹤0.01% 846
2026
Q1 		$1.04M Buy
20,543
+816
+4% +$38.1K ﹤0.01% 853
2025
Q4 		$582K Buy
19,727
+4,331
+28% +$118K ﹤0.01% 926
2025
Q3 		$398K Sell
15,396
-95,302
-86% -$2.66M ﹤0.01% 974
2025
Q2 		$3.05M Sell
110,698
-641,106
-85% -$16.9M ﹤0.01% 763
2025
Q1 		$21.3M Sell
751,804
-3,887
-0.5% -$138K 0.02% 631
2024
Q4 		$31.4M Sell
755,691
-858,622
-53% -$41M 0.02% 574
2024
Q3 		$108M Buy
1,614,313
+167,596
+12% +$15.4M 0.07% 256
2024
Q2 		$172M Sell
1,446,717
-99,112
-6% -$12.5M 0.13% 159
2024
Q1 		$165M Buy
1,545,829
+463,960
+43% +$46.8M 0.11% 190
2023
Q4 		$108M Buy
1,081,869
+154,112
+17% +$13M 0.08% 261
2023
Q3 		$95.8M Buy
927,757
+81,062
+10% +$9.04M 0.08% 275
2023
Q2 		$103M Sell
846,695
-117,902
-12% -$15.7M 0.08% 266
2023
Q1 		$148M Sell
964,597
-18,989
-2% -$3.13M 0.11% 198
2022
Q4 		$177M Sell
983,586
-30,323
-3% -$4.96M 0.14% 165
2022
Q3 		$120M Sell
1,013,909
-6,393
-0.6% -$970K 0.1% 226
2022
Q2 		$146M Sell
1,020,302
-21,951
-2% -$3.14M 0.11% 205
2022
Q1 		$180M Sell
1,042,253
-38,774
-4% -$6.53M 0.12% 184
2021
Q4 		$275M Sell
1,081,027
-81,008
-7% -$23.7M 0.17% 128
2021
Q3 		$447M Sell
1,162,035
-104,200
-8% -$38.4M 0.28% 81
2021
Q2 		$298M Buy
1,266,235
+65,017
+5% +$11.6M 0.18% 132
2021
Q1 		$157M Buy
1,201,218
+260,263
+28% +$37.7M 0.1% 229
2020
Q4 		$98.3M Sell
940,955
-73,385
-7% -$7.42M 0.06% 344
2020
Q3 		$71.8M Sell
1,014,340
-58,489
-5% -$4.08M 0.05% 391
2020
Q2 		$68.9M Buy
+1,072,829
New +$58.8M 0.05% 399

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Sumitomo Mitsui Trust Group's MRNA Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group increased its Moderna (MRNA) stake by 1% in Q2 2026, buying an estimated $11.1K and bringing the position to 20,757 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Sumitomo Mitsui Trust Group first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $447M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 20,757 shares of Moderna worth $1.45M as of Q2 2026.
  • Sumitomo Mitsui Trust Group bought 214 Moderna shares in Q2 2026, an estimated $11.1K.
  • Moderna made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #846 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Sumitomo Mitsui Trust Group's Moderna position peaked at $447M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.